Florey Institute of Neuroscience and Mental Health, Parkville, Vic., Australia.
Department of Anatomy & Neuroscience, University of Melbourne, Parkville, Vic., Australia.
Neurogastroenterol Motil. 2019 Nov;31(11):e13692. doi: 10.1111/nmo.13692. Epub 2019 Aug 2.
Because M1 muscarinic receptors are expressed by enteric neurons, we investigated whether positive allosteric modulators of these receptors (M1PAMs) would enhance colorectal propulsion and defecation in dogs, mice, and rats.
The potencies of the M1PAMs, T662 or T523, were investigated using M1 receptor-expressing CHO cells. Effectiveness of M1PAMs on defecation was investigated by oral administration in mice and rats, by recording propulsive contractions in anaesthetized rats and by recording high amplitude propagating contractions in dogs.
PAM EC50 values in M1 receptor-expressing CHO cells were 0.7-1.8 nmol/L for T662 and 8-10 nmol/L for T523. The compounds had 1000-fold lower potencies as agonists. In anesthetized rats, both compounds elicited propulsive colorectal contractions, and in dogs, mice, and rats, oral administration increased fecal output. No adverse effects were observed in conscious animals. M1PAMs triggered propagated high amplitude contractions and caused defecation in dogs. Nerve-mediated contractions were enhanced in the isolated mouse colon. M1PAMs were equi-effective in rats with or without the pelvic nerves being severed. In two models of constipation in mice, opiate-induced constipation and constipation of aging, defecation was induced and constipation was reversed.
M1PAMs act at targets sites in the colorectum to enhance colorectal propulsion. They are effective across species, and they reverse experimentally induced constipation. Previous studies have shown that they are safe in human. Because they provide an enhancement of physiological control rather than being direct agonists, they are predicted to provide effective treatment for constipation.
由于 M1 毒蕈碱受体存在于肠神经元中,我们研究了这些受体的正变构调节剂(M1PAMs)是否会增强犬、鼠和大鼠的结肠推进和排便。
使用表达 M1 受体的 CHO 细胞研究 M1PAMs(T662 或 T523)的效力。通过在小鼠和大鼠中口服给药、在麻醉大鼠中记录推进性收缩以及在犬中记录高振幅传播收缩来研究 M1PAMs 对排便的影响。
T662 在表达 M1 受体的 CHO 细胞中的 EC50 值为 0.7-1.8 nmol/L,而 T523 的 EC50 值为 8-10 nmol/L。这些化合物作为激动剂的效力低 1000 倍。在麻醉大鼠中,两种化合物均诱发结肠推进性收缩,在犬、鼠和大鼠中,口服给药增加粪便排出量。在清醒动物中未观察到不良反应。M1PAMs 触发传播性高振幅收缩并引起犬排便。在分离的小鼠结肠中增强了神经介导的收缩。M1PAMs 在有或没有切断盆神经的大鼠中均有效。在两种小鼠便秘模型(阿片类药物诱导的便秘和衰老引起的便秘)中,诱导了排便并逆转了便秘。
M1PAMs 作用于大肠中的靶部位以增强结肠推进。它们在多种物种中均有效,可逆转实验性便秘。先前的研究表明它们在人体中是安全的。由于它们提供了对生理控制的增强而不是直接激动剂,因此预计它们将为便秘提供有效的治疗。